ALGN stock sentiment todayAlign Technology, Inc.
Sentiment verdict
Gossip first, financials second — COLD at 75% confidence.
Last updated · cached analysis, refreshes periodically
ALGN
Align Technology, Inc.ALGN is grappling with a 'perfect storm' of macroeconomic pressure on discretionary spending and intensifying low-cost competition in the clear aligner market.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for ALGN. Not financial advice.
Price · last 12 months
Gossip
The narrative has shifted from ALGN being a high-growth tech disruptor to a cyclical medical device play struggling with consumer fatigue. Recent sentiment is weighed down by guidance cuts and the perception that the 'easy growth' in adult orthodontics is over.
- ·Weakening consumer discretionary spending
- ·Market share erosion from generic/DTC competitors
- ·Stagnant case shipment growth in key North American markets
- ·High sensitivity to interest rate environments affecting patient financing
Financial
While ALGN maintains high gross margins (~70%) and a clean balance sheet with no long-term debt, revenue growth has stalled. The valuation remains high relative to its current low-double-digit growth profile, making it vulnerable to further rerating.
- ·Forward P/E: ~18x (compressed from historical 40x+)
- ·Operating Margin: ~15-18% (under pressure)
- ·Debt-to-Equity: 0.00
- ·Free Cash Flow: Consistently positive but volatile
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Mixed conviction — no decisive signal from insiders or the holder base.
- ·Institutions added more shares than they cut last quarter.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·Continued decline in average selling price (ASP) due to product mix
- ·Entry of aggressive players like Envista and Dentsply Sirona into the digital workflow space
- ·China macro-softness impacting international expansion targets
Peer temperature
How direct competitors stack up against ALGN right now.
- NEUTRALNVSTEnvista Holdings
NEUTRAL — trading at a lower valuation but facing similar destocking and dental implant headwinds.
See full analysis → - COLDXRAYDentsply Sirona
COLDER — struggling with deeper internal restructuring and regulatory hurdles that outweigh ALGN's product dominance.
See full analysis → - HOTSTRAUMANNStraumann Group
HOTTER — demonstrating superior resilience in premium dental markets and stronger growth in emerging economies.
See full analysis →
- ALGN-9.3%
- NVST-4.7%
- XRAY-17.4%
- STRAUMANN—
AI-generated analysis for informational purposes only. Not financial advice.